sponsored
PatientsVille.com Logo

PatientsVille

Docetaxel Medical Research Studies

Up-to-date List of Docetaxel Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Docetaxel Medical Research Studies

Rank Status Study
1 Unknown  Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel * Sunitinib;   Drug: Docetaxel
Outcome Measures: Primary: CEC/CEP spikes induced by MTD Docetaxel in patients treated with Docetaxel/sunitinib relative to Docetaxel monotherapy;   Response rate and length of treatment holidays relative to Docetaxel monotherapy
2 Unknown  Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Docetaxel;   Drug: Docetaxel, cisplatin;   Drug: Docetaxel, S-1
Outcome Measures: response rate;   time to progression
3 Recruiting A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Fulvestrant
Outcome Measures: Progression Free Survival;   Overall Response Rate;   Overall Survival
4 Recruiting Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Conditions: Recurrent;   Head and Neck Cancer
Interventions: Radiation: SBRT;   Drug: Cetuximab;   Drug: Docetaxel
Outcome Measures: Locoregional progression-free survival (PFS) of previously-irradiated patients with SCCHN treated with SBRT, cetuximab, and Docetaxel;   Acute and late toxicities associated with the above therapy
5 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
Outcome Measures: Disease Progression;   Effect of Docetaxel and Reolysin on circulating tumour cells;   PSA change rate;   Objective Response;   Overall Survival;   Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination;   Prognostic/Predictive molecular response
6 Recruiting Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: Docetaxel;   Procedure: prostate biopsy;   Other: laboratory biomarker analysis;   Drug: phenelzine sulfate
Outcome Measures: Proportion of patients who experience a PSA decline of at least 30%;   Duration of progression free survival after initiation of combination phenelzine and Docetaxel therapy;   Response rate in measurable disease by RECIST criteria;   Maximum change in PSA;   Toxicity of the regimen;   Time to death from all causes;   Frequency of MAOA overexpression in CRPC tumors that are progressing on Docetaxel;   HIF-1alpha expression in circulating tumor cells as a potential measure of MAO and activity;   MAOA expression in circulating tumor cells and comparison to biopsy MAOA expression
7 Recruiting Docetaxel and Lycopene in Metastatic Castration-resistant Prostate Cancer
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: Lycopene and Docetaxel
Outcome Measures: Determination of the Maximum Tolerated Dose of Lycopene when given in combination with Docetaxel;   IGF1 signaling inhibition at MTD;   Pharmacokinetic assessment of Docetaxel and lycopene;   Assessment of plasma levels of IL6, IGF1, IGF-2, and IGFBP3; and IGF1R level
8 Recruiting Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Docetaxel;   Dietary Supplement: Lycopene
Outcome Measures: PSA response (proportion of subjects achieving a >= 50% reduction in PSA from baseline);   Objective response rate as assessed by RECIST criteria in either visceral or lymph node metastases;   Time to PSA progression;   Toxicity of combined Docetaxel + lycopene therapy
9 Recruiting Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients
Condition: Prostate Cancer
Interventions: Drug: Docetaxel every 3 weeks + Prednisone;   Drug: Docetaxel weekly+ Prednisone
Outcome Measures: Feasibility of 2 different protocols of Docetaxel chemotherapy;   Overall Survival;   Geriatric evaluation;   Number of patients with Adverse Events;   Quality of Life;   Vital signs measurement;   Prostate-specific antigen (PSA) measurements
10 Recruiting A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Conditions: Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions: Drug: Alpharadin® (Radium-223 dichloride) + Docetaxel;   Drug: Docetaxel
Outcome Measures: Dose-escalation: Assessment of dose-limiting toxicities;   Expanded safety cohort: Safety of combining Alpharadin® with Docetaxel (incidence and severity of adverse events and serious adverse events, changes from baseline in laboratory variables, vital signs and physical examination);   Signs of long-term radiation toxicity: incidence of manifestations of potential late toxicity, such as new primary cancers and bone marrow changes (acute myelogenous leukaemia, myelodysplastic syndrome, and aplastic anaemia);   Exploratory efficacy measurements of Alpharadin® in combination with Docetaxel versus Docetaxel alone such as changes in bone markers, PSA and CTC, time to progression and overall survival;   Exploratory patient self-reporting of pain intensity
11 Recruiting Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Condition: Squamous Cell Carcinoma of the Oropharynx, Larynx, or Hypopharynx
Interventions: Drug: Cisplatin;   Radiation: IMRT;   Drug: Docetaxel;   Drug: Cetuximab
Outcome Measures: Evaluate the efficacy of radiotherapy with concurrent Docetaxel-cetuximab vs. cisplatin in patients with locally advanced HNSCC and increased tumoral ERCC1 expression, as measured by time to progression (TTP);   Evaluate the efficacy of radiotherapy with concurrent Docetaxel-cetuximab vs. cisplatin in patients with PULA HNSCC and decreased/normal tumoral ERCC1 expression, as measured by TTP;   Evaluate the efficacy of radiotherapy with concurrent Docetaxel-cetuximab vs. cisplatin in all patients irrespective of ERCC1 status, as measured by TTP;   Prospectively validate the candidate cutpoint for decreased/normal vs. increased ERCC1 [4F9] expression in patients treated with cisplatin-IMRT;   Prospectively investigate two sets of radiologic interpretive criteria, including RECIST 1.1 and integrated PET/CT, for the designation of complete response (CR), and to compare the ability of the two CR classifications to accurately predict 2-year TTP.
12 Recruiting Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients
Condition: Advanced Cancer
Interventions: Drug: DT-LM;   Drug: Docetaxel
Outcome Measures: The safety and tolerability;   Assessment of pharmacokinetics of DT-LM and Taxotere: AUC and Cmax;   Objective tumour response according to RECIST
13 Recruiting Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: intravenous Docetaxel with intraperitoneal oxaliplatin;   Drug: intravenous oxaliplatin with intraperitoneal Docetaxel
Outcome Measures: To determine the safest and maximum tolerated dose regimen for IV oxaliplatin with intraperitoneal Docetaxel and IV oxaliplatin with intraperitoneal Docetaxel in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.;   To assess quality of life
14 Not yet recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: VEGFR/PDGFR dual kinase inhibitor X-82;   Drug: Docetaxel;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography/computed tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (Pharmacodynamic study);   Changes in the FLT PET/CT vascular parameters for VEGF/PDGF dual kinase inhibitor X-82;   Changes in the FLT PET/CT vascular parameters for the combination of VEGFR/PDGFR dual kinase inhibitor X-82 and Docetaxel;   Disease response assessed by the RECIST 1.1;   Changes in VEGF;   Pharmacokinetic parameters of VEGFR/PDGFR dual kinase inhibitor X-82
15 Recruiting Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment
Condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions: Drug: Selumetinib 75 mg;   Drug: Docetaxel 75 mg/m2;   Drug: Docetaxel 60 mg/m2;   Drug: Placebo
Outcome Measures: Progression-Free Survival (PFS);   Overall Survival (OS);   Objective Response Rate (ORR);   Duration of Response;   Change in tumour size at week 6;   The safety and tolerability profile of Selumetinib in Combination With Docetaxel;   Correlation of KRAS mutation status with efficacy of treatment;   The effect on health-related quality of life (HRQoL);   The pharmacokinetics (PK) of selumetinib and N-desmethyl selumetinib measured by AUC, Cmax.;   Symptom improvement rate (using ASBI from LCSS);   Time to symptom progression (using ASBI from LCSS)
16 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: pasireotide;   Drug: prednisone
Outcome Measures: Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with Docetaxel and prednisone;   All specific types of toxicity as assessed via NCI CTCAE version 4.0;   Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with Docetaxel;   Percentage prostate-specific antigen (PSA) decline noted;   Time to Progression (TTP);   Overall Survival (OS);   Pharmacokinetics (PK) parameters;   Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS;   Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS
17 Recruiting A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Conditions: Non-Small-Cell Lung Adenocarcinoma;   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV;   Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Arm A: single agent Docetaxel;   Drug: Arm B: Combination of ganetespib and Docetaxel
Outcome Measures: Overall survival;   Progression-free survival;   Objective Response Rate;   Disease control rate;   Duration of treatment;   Duration of response;   Symptom improvement;   Qualitative and quantitative toxicities;   Clinical efficacy in biomarker-defined subpopulations.;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Exploratory biomarker analyses
18 Unknown  A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: Docetaxel-PNP
Outcome Measures: The maximum tolerated dose (MTD) of Docetaxel-PNP;   The recommended phase II dose of Docetaxel-PNP;   The Dose Limiting Toxicity (DLT);   The pharmacokinetics of Docetaxel-PNP on Day 1 of 1st cycle (AUC, CL, T1/2, Tmax, Cmax, Vdss);   Objective response rate
19 Recruiting Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions: Drug: cisplatin;   Drug: Docetaxel;   Biological: cetuximab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy
Outcome Measures: Disease-free survival (DFS) (Phase II);   Overall survival (OS) (Phase III);   Local-regional failure (LRF);   Distant metastasis (DM);   Patterns of cancer failure (local, regional, distant);   Acute toxicity profiles during and at completion of treatment, graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0;   Late toxicity profiles, graded according to the NCI CTCAE version 4.0;   Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N) scores;   MD Anderson Symptom Inventory - Head & Neck (MDASI-HN) scores;   MD Anderson Dysphagia Inventory (MDADI) scores;   EuroQol (EQ-5D) scores;   Quality adjusted life year (QALY);   Translational research analysis
20 Recruiting Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel and epirubicin;   Drug: Docetaxel and epirubicin plus endostatin
Outcome Measures: Clinical/pathological response;   Number of participants with adverse events;   Quality of life;   Number of adverse events reported during neoadjuvant therapy

These studies may lead to new treatments and are adding insight into Docetaxel etiology and treatment.

A major focus of Docetaxel research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Docetaxel